EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitFallberichtOpen Access · CC BY 4.0

New SAMD9L heterozygous mutation leading to myelodysplastic syndrome and acute myeloid leukemia: A case report and review of the literature

Dania A Monagel iD

Cancer Reports · 2023

DOI: 10.1002/cnr2.1797 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Cancer Reports, 2023. Verfasst von Dania A Monagel. Beteiligte Einrichtung: College of Medicine, King Saud bin Abdulaziz University for Health Sciences, Jeddah, Saudi Arabia. Hauptthemen laut MEDLINE: Myelodysplastic Syndromes, Leukemia, Myeloid, Acute, Tumor Suppressor Proteins. Die Arbeit nennt 20 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

SAMD9L mutation is linked to the development of myeloid neoplasm. The mutation has a wide range of clinical presentations involving neurological, immunological, and hematological manifestations. Until now, limited data regarding different variants of this genetic mutation existed. Here we present a 6‐year‐old girl who presented with acute myeloid leukemia/myelodysplastic changes and who carries a new germline variant mutation in the SAMD9L gene. Case Presentation A 6‐year‐old girl who presented initially as a case of immune thrombocytopenic purpura (ITP) was later diagnosed with acute myeloid leukemia and myelodysplastic changes. In addition, she was found to have a new germline variant mutation in the SAMD9L gene (other known pathogenic variants known to cause ataxia pancytopenia syndrome). She was treated with chemotherapy followed by haplo identical transplant from her unaffected father. She is alive 30 months post‐transplant and in complete remission with full donor chimerism. Her initial brain MRI showed mild prominence of the anterior (superior) vermis folia, suggesting mild atrophy. Ongoing surveillance for accompanied neurological manifestation is ongoing, although the patient is asymptomatic.

Conclusion

For SAMD‐9L‐related disorder, a careful approach must be taken when a patient presents with a suspicious clinical feature even without a well‐known genetic mutation giving the diverse presentation across affected members within the same family. In addition, other associated abnormalities should be monitored long‐term.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Myelodysplastic SyndromesLeukemia, Myeloid, AcuteTumor Suppressor ProteinsHumansFemaleChildExome Sequencing

Stichwörter der Autor:innen

SAMD9Lacute myeloid leukemiamyelodysplastic syndromepediatrictransplant

Substanzen

SAMD9L protein, humanTumor Suppressor Proteins

Autor:innen und Institutionen

  • College of Medicine, King Saud bin Abdulaziz University for Health Sciences, Jeddah, Saudi Arabia.
  • King Abdullah International Medical Research Center, Jeddah, Saudi Arabia.
  • Department of Oncology, Ministry of the National Guard- Health Affairs, Jeddah, Saudi Arabia.

ORCID-Profile: Dania A Monagel

Zitieren

APA

Monagel, D. A. (2023). New SAMD9L heterozygous mutation leading to myelodysplastic syndrome and acute myeloid leukemia: A case report and review of the literature. Cancer Reports. https://doi.org/10.1002/cnr2.1797

Vancouver

Monagel DA. New SAMD9L heterozygous mutation leading to myelodysplastic syndrome and acute myeloid leukemia: A case report and review of the literature. Cancer Reports. 2023. doi:10.1002/cnr2.1797

BibTeX
@article{Monagel2023,
  author = {Monagel, Dania A},
  title = {New SAMD9L heterozygous mutation leading to myelodysplastic syndrome and acute myeloid leukemia: A case report and review of the literature},
  journal = {Cancer Reports},
  year = {2023},
  doi = {10.1002/cnr2.1797}
}
Kostenlos starten →